2 assets in Breast Ductal Adenocarcinoma

Therapeutic assets addressing Breast Ductal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Exemestane Breast Ductal Adenocarcinoma	Dana-Farber Cancer Institute	P2	CCC (53)
Tamoxifen Breast Ductal Adenocarcinoma	Dana-Farber Cancer Institute	P2	CCC (53)